Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX)

CAPS Rating: 2 out of 5

A biopharmaceutical company focusing on the development and commercialization of innovative therapeutic products to treat the unmet medical needs of patients with debilitating conditions and life-threatening diseases.

Results 1 - 20 of 39 : 1 2 Next »

Recs

0
Member Avatar pchop123 (78.35) Submitted: 4/14/2014 11:02:02 AM : Outperform Start Price: $3.68 PGNX Score: -4.93

the pendlelum is now swinging to the positive

Recs

0
Member Avatar wmansvelt (45.90) Submitted: 3/18/2014 3:40:04 PM : Underperform Start Price: $4.70 PGNX Score: +23.44

Although there is great potential and the profitability can change quickly the costs look excessive to say the least. I do note that there is no long term debt. this must indicate confidence of robust financial backers. i think there is a long way to go for the company

Recs

0
Member Avatar 10qdetective (< 20) Submitted: 3/4/2014 1:11:10 AM : Outperform Start Price: $4.74 PGNX Score: -23.82

Contrary to investors’ bearish sentiment that further testing of the clinical utility of PSMA-ADC might be pointless due to toxicity concerns is unfounded: Robert Israel, MD, one of the study authors and executive vice president of medical affairs at Progenics, pointed out to Medscape Medical News that both of the patients who died had predisposing conditions.
"One had an indwelling central line [known to increase risk of developing sepsis] and the other had repeated urinary tract infections," said Dr. Israel. "The patients were also heavily pretreated and didn't have much in the way of other options."
As a new class of biological therapeutics, the ADC market is still in its infancy. Nonetheless, skeptics might want to spend a Saturday reading up on the managed benefits of these highly potent drugs in the context of understood off-target toxicities.
As observed by Dr. Israel: "This [two septic-related deaths with PSMA-ADC] is not going to make a difference to clinicians. Anytime you drop the white blood cell count, there is a risk associated with it."

Recs

0
Member Avatar HIGHG33K (74.65) Submitted: 2/4/2014 12:21:59 AM : Outperform Start Price: $4.71 PGNX Score: -30.80

FDA will approve

Recs

0
Member Avatar SqwiiTrader (39.18) Submitted: 11/4/2013 6:46:30 PM : Outperform Start Price: $3.95 PGNX Score: -15.54

Cow

Recs

3
Member Avatar zzlangerhans (99.74) Submitted: 10/31/2013 9:45:50 AM : Outperform Start Price: $4.04 PGNX Score: -17.36

The most important thing for a trader to know about Progenics is that the momentum swings in the stock have a lot of, well, momentum. Long after it seems all the negatives are priced in, the stock keeps dropping. The decline will pause for a few days to suck the bottom feeders in, and then the bottom will drop out again. A similar effect occurs when the stock is moving in the other direction. For that reason, I don't expect my CAPS picks on Progenics to do well in the short term. In the mid term, with one doozy of an exception, I've hit it every time. Like many of the other stocks that I've scored on time and time again in CAPS, I've never held or shorted a share of Progenics in real life.

The main upcoming catalyst is an Ad Comm for Relistor for non-cancer opioid-induced constipation on March 10, to be convened in response to a formal appeal by Salix of the 2012 CRL. Data from the phase II trial of PSMA for prostate cancer will be presented at a conference in early 2014. I'm not expecting great things from either of these programs - Relistor royalties from cancer OIC have been anemic, and the company kept the PSMA program on the back burner for years. Nevertheless, the worm will once again turn on Progenics at some point and the stock will likely massively overshoot fair valuation as it has done many times before.

Recs

0
Member Avatar genedom (98.80) Submitted: 9/9/2013 3:18:02 AM : Outperform Start Price: $5.90 PGNX Score: -51.48

Short term momentum

Recs

0
Member Avatar rknapton (< 20) Submitted: 8/22/2013 4:56:09 PM : Underperform Start Price: $5.19 PGNX Score: +44.65

Short. Pharma. Revs down. Massive losses. Sells more stock than drugs.

Recs

0
Member Avatar scrubs62074 (88.69) Submitted: 2/20/2013 10:59:26 AM : Outperform Start Price: $2.90 PGNX Score: +0.88

Bullish MACD crossover on 02/20/13

Recs

0
Member Avatar MicroMagic (< 20) Submitted: 9/25/2012 11:51:15 PM : Underperform Start Price: $3.32 PGNX Score: +22.09

This company has a bright future with it's injectable drug to cure the terrible affliction many pain killer addicts have with constipation.

Since there is no known cure for constipation anywhere out there.

Recs

0
Member Avatar SamsaricSufferer (< 20) Submitted: 7/4/2012 8:14:51 PM : Outperform Start Price: $10.39 PGNX Score: -101.69

PDUFA coming up.

Recs

0
Member Avatar GameEmag (< 20) Submitted: 1/29/2012 5:26:11 PM : Underperform Start Price: $9.54 PGNX Score: +105.30

The recent jump in share price (Dec. '11-Current) has no basis in reality and seems fueled only by investors given to hoping for the best and low volume days allowing an easy path for pumping prices temporarily. To borrow words from so many market pundits it is the picture of "irrational exuberance."

Recs

0
Member Avatar 1stMartian (23.36) Submitted: 12/6/2011 11:26:56 PM : Underperform Start Price: $7.41 PGNX Score: +99.86

Piggy back off Z's analysis.

Recs

0
Member Avatar targetphil3 (< 20) Submitted: 10/1/2010 6:10:41 PM : Outperform Start Price: $5.05 PGNX Score: -92.24

CEO buying shares on regular basis

Recs

0
Member Avatar nhanhsong (< 20) Submitted: 6/23/2010 6:09:13 AM : Underperform Start Price: $5.62 PGNX Score: +106.41

If PGNX can't find a new partner for RELISTOR this year, it will face some difficulty with finance.

Recs

0
Member Avatar roalercoaster (26.49) Submitted: 3/29/2010 10:25:11 PM : Outperform Start Price: $5.22 PGNX Score: -90.26

Upcoming Catalyst

Recs

0
Member Avatar BeaterOfFools (40.23) Submitted: 3/13/2010 7:41:36 PM : Outperform Start Price: $5.28 PGNX Score: -94.06

Red Raider is Lord

Recs

0
Member Avatar FoolBeater (22.56) Submitted: 3/13/2010 7:24:08 PM : Outperform Start Price: $5.28 PGNX Score: -94.06

Lord knows

Recs

0
Member Avatar tdmitchell08 (< 20) Submitted: 2/9/2010 1:08:29 AM : Outperform Start Price: $4.52 PGNX Score: -94.98

I need help. I think this company will do well based on they look like they are at a low point, but will bounce back. If someone would like to let me know why I am right or wrong I would apprecaite it.

Recs

0
Member Avatar Contralogic (27.11) Submitted: 1/23/2010 10:11:50 AM : Outperform Start Price: $4.60 PGNX Score: -91.49

Go Bio!

Results 1 - 20 of 39 : 1 2 Next »

Featured Broker Partners


Advertisement